Ashley Stevens of Boston University is conducting a survey of indirect cost
rates being charged on clinical trials.  He currently has eighteen
responses with the following results:

Mean    22.8%   Deviation       3.3%
Median  23.5%   Standard Dev.   4.2%
 Variance        0.2%

These results are not noticeably different from those determined in a study
carried out by U. Conn. Health Center about eighteen months ago.  With
thirty respondents, they found:

Mean  23.6%
Median  25.0%
Standard Dev. 5.0%
Variance  0.3%

Ashley would like to increase the response base for his study, and since he
is not a subscriber to resadm-l, asked me if I would post for him.  Replies
should be  sent to him directly at:

 xxxxxx@bu.edu

He has committed to me that he will also ask me to post the results of his
survey to resadm-l!

His specific questions are:

1.      What is your institution's IDC for company sponsored clinical trials?

2.      What is the basis for the IDC calculation (TDC, MTDC, are patient care
 charges excluded, etc?)

3.      Do you levy a separate IRB charge?

4.      What is your NIH IDC rate for clinical trials?

5.      Are you considering any change in your clinical trial IDC rates?

Many thanks.

Ashley Stevens
Community Technology Fund
Boston University
80 E. Concord Street, Suite L307C
Boston, MA 02118-2394

Ph:  (617) 638-4540
Fax: (617) 638-4515
xxxxxx@acs.bu.edu
--------------------------------------------------------------------------
Doug Wilkerson, Ph.D.              VOICE:    (419) 381-4252
Assoc. V.P. for Research           FAX:      (419) 381-4262
Professor of Pharmacology          e-mail:   xxxxxx@GEMINI.MCO.EDU
Medical College of Ohio            WEB:      http://www.mco.edu/research
3000 Arlington Ave.
Toledo, OH 43614